Skip to main content

Table 1 Baseline characteristics of patients with paroxysmal or persistent AF

From: Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial

Baseline patient characteristics

Paroxysmal AF (n = 771)

Persistent AF (n = 463)

P value

Demographics

Age – years (mean±SD)

66.75±9.84

68.78±8.54

0.0002

Age classification:

   

• <65 years old

298 (38.65)

133 (28.73)

0.0016

• 65-75 years old

304 (39.43)

219 (47.30)

• ≥75 years old

169 (21.92)

111 (23.97)

Female sex

351 (45.53)

136 (29.37)

<0.0001

AF details

≥2 episodes of AF in the previous 6 months

433 (56.68)

110 (24.72)

<0.0001

Cardioversion

637 (82.62)

453 (97.84)

<0.0001

Time to cardioversion ≤48 hours

533 (69.13)

0

-

Time to cardioversion >48 hours - ≤7 days

104 (13.48)

0

-

Time to cardioversion >7 days - ≤3 months

0

260 (56.15)

-

Time to cardioversion >3 months

0

193 (41.68)

-

Coexisting conditions

HF/Left ventricular ejection fraction <40%

32 (4.15)

63 (13.61)

<0.0001

Stroke/TIA/Systemic embolism

48 (6.23)

27 (5.83)

0.7790

Hypertension for 6 months or more

677 (87.81)

372 (80.35)

0.0004

Diabetes mellitus

115 (14.92)

64 (13.82)

0.5976

Documented coronary disease

34 (4.41)

19 (4.10)

0.7973

Peripheral artery disease

28 (3.63)

20 (4.32)

0.5450

Renal dysfunction

19 (2.46)

14 (3.02)

0.5553

Neoplasia

27 (3.5)

11 (2.38)

0.2676

Alcohol abuse

6 (0.78)

10 (2.16)

0.0378

Cardiovascular therapies

• No antithrombotic treatment

182 (23.61)

17 (3.67)

<0.0001

• Warfarin

192 (24.90)

404 (87.26)

• Antiplatelet agent

385 (49.94)

24 (5.18)

• Warfarin + antiplatelet agent

12 (1.56)

18 (3.89)

ACE inhibitors

411 (53.31)

275 (59.40)

0.0372

Valsartan

389 (50.45)

238 (51.40)

0.7466

Aldosterone blockers

17 (2.20)

55 (11.88)

<0.0001

Class I antiarrhythmic agents

304 (39.43)

113 (24.41)

<0.0001

Amiodarone

181 (23.48)

219 (47.30)

<0.0001

Risk stratification schemes for thromboembolic events

CHADS2 - score

• 0

55 (7.13)

38 (8.21)

0.3946

• 1

448 (58.11)

251 (54.21)

• ≥2

268 (34.76)

174 (37.58)

Risk stratification schemes for bleeding events

   

OBRI - score

   

• 0

248 (32.17)

113 (24.41)

0.0120

• 1-2

518 (67.19)

345 (74.51)

• 3-4

5 (0.65)

5 (1.08)

Back to article page